AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Group 1 - AIM ImmunoTech Inc. has published a new CEO Corner segment on its website, featuring insights from CEO Thomas Equels regarding Advanced Recurrent Ovarian Cancer and the company's clinical development milestones [1] - The company focuses on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [2] - AIM's lead product is Ampligen® (rintatolimod), which is a first-in-class investigational drug with broad-spectrum activity in clinical trials [2]